Search
moon
sun

T67. Tuberculosis

A. Introduction and epidemiology

1.
๊ฒฐํ•ต์€ ๊ฐ์—ผ๋ณ‘์ค‘ ๋‘ ๋ฒˆ์งธ๋กœ ๋†’์€ ์‚ฌ๋ง์œ ๋ฐœ์›์ธ, HIVํ™˜์ž์—์„œ์˜ ์ฃผ์š”์‚ฌ๋ง์›์ธ์ด๋‹ค.
2.
์ง€๋‚œ 20๋…„๊ฐ„ ์น˜๋ฃŒ์—๋„ ๋ถˆ๊ตฌํ•˜๊ณ  ์•ฝ๋ฌผ๋‚ด์„ฑ๊ณผ HIV coinfection์€ ์ „ ์„ธ๊ณ„์  ๋ฌธ์ œ
3.
์ง€์†์ ์ธ ๊ด€๋ฆฌ์™€ ์˜ˆ๋ฐฉ์ด ํ•„์š”ํ•˜๋ฉฐ ์ด๋Š” ๊ณ ์œ„ํ—˜๊ตฐ์˜ ์ธ์ง€์™€ ์น˜๋ฃŒ๊ฐ€ ํ•„์š”ํ•จ
ํ˜ˆ์•ก, ๋ฆผํ”„์ ˆ, ์ง์ ‘ ์ ‘์ด‰์„ ํ†ตํ•ด ํผ์ง
Lung์˜ apex, upper lobe์˜ posterior segment, renal cortex, meninges, long bone์˜
epiphyses, vertebrae ๋“ฑ์˜ high oxygen์ด ์žˆ๋Š” ๊ณณ์—์„œ ์ƒ์กด ๋ฐ ์ž ๋ณต
์ž ๋ณต๊ธฐ ๋™์•ˆ์—๋Š” skin test์—์„œ๋งŒ ๋‚˜ํƒ€๋‚˜๋ฉฐ ๋…ธ์ถœ 1-2๊ฐœ์›” ํ›„๋ถ€ํ„ฐ ์–‘์„ฑ๋ฐ˜์‘
(1-13%๊ฐ€ active dz๋กœ ๋ฐœํ˜„, children, HIV ๊ฐ™์€ high risk ์—์„œ๋Š” 20%๊นŒ์ง€)

B. Pathophysiology

โ€ข
Mycobacterium tuberculosis : slow-growing aerobic rod
โ€ข
์‚ฌ๋žŒ๊ฐ„ ์ „์—ผ inhalation of droplet nuclei in to the lung
โ€ข
Active Tb์˜ saliva, sputum์ด ๊ฐ€์žฅ ์ „์—ผ๋ ฅ ๋†’์œผ๋ฉฐ ๋…ธ์ถœ ํ›„ 30%๊ฐ€ ๋ฐœํ˜„๋จ

B1. ์ผ์ฐจ๊ฒฐํ•ต ๋ฐ ์ž ๋ณต๊ฒฐํ•ต

โ€ข
Granuloma(=tubercles), 1์ฐจ ๊ฐ์—ผ์˜ ์ฆ๊ฑฐ
โ€ข
Ghon complex (granuloma๊ฐ€ ๊ฑด๋ฝ๊ดด์‚ฌ ๋ฐ ์„ํšŒํ™”๋œ ๋ณ‘๋ณ€) ๋‚˜ํƒ€๋‚จ
โ€ข
ํ˜ˆ์•ก, ๋ฆผํ”„์ ˆ, ์ง์ ‘ ์ ‘์ด‰์„ ํ†ตํ•ด ํผ์ง
โ€ข
Lung์˜ apex, upper lobe์˜ posterior segment, renal cortex, meninges, long bone์˜ epiphyses, vertebrae ๋“ฑ์˜ high oxygen์ด ์žˆ๋Š” ๊ณณ์—์„œ ์ƒ์กด ๋ฐ ์ž ๋ณต
โ€ข
์ž ๋ณต๊ธฐ ๋™์•ˆ์—๋Š” skin test์—์„œ๋งŒ ๋‚˜ํƒ€๋‚˜๋ฉฐ ๋…ธ์ถœ 1-2๊ฐœ์›” ํ›„๋ถ€ํ„ฐ ์–‘์„ฑ๋ฐ˜์‘
โ€ข
๋…ธ์ถœ์ž ์ค‘ 25%๊ฐ€ ๊ฐ์—ผ, 1~13%๊ฐ€ active dz๋กœ ๋ฐœํ˜„, children, HIV ๊ฐ™์€ high risk์—์„œ๋Š” 20%๊นŒ์ง€

B2. ์žฌํ™œ๋™์„ฑ ๊ฒฐํ•ต

โ€ข
Host์˜ ๋ฉด์—ญ์ƒํƒœ์— ์˜ํ–ฅ
โ€ข
Reactivation์€ HIV, 50์„ธ ์ด์ƒ, ์•”, ์ด์‹ํ™˜์ž๋“ค์—์„œ ๋งŽ๋‹ค.

C Clinical features

C1. ์ผ์ฐจ๊ฒฐํ•ต

โ€ข
์ฒ˜์Œ์—๋Š” ์ฃผ๋กœ ๋ฌด์ฆ์ƒ, skin test/ ํ‰๋ถ€ ์ดฌ์˜ ์ด์ƒ์†Œ๊ฒฌ์œผ๋กœ ๋‚˜ํƒ€๋‚จ
โ€ข
ํ™œ๋™์„ฑ์ด๋ฉด ์ฃผ๋กœ fever, malaise, wt loss, chest pain
โ€ข
Chest x-ray : Pneumonitis, hilar adenopathy

C2. ์žฌํ™œ๋™์„ฑ ๊ฒฐํ•ต

โ€ข
Systemic/ pulmonary ์ฆ์ƒ
โ€ข
์ฃผ์ฆ์ƒ์€ ์ผ์ฐจ๊ฒฐํ•ต๊ณผ ๋น„์Šทํ•˜๋‹ค.
โ€ข
Lung๊นŒ์ง€ ํผ์ง€๋Š” ๊ฒฝ์šฐ productive cough, hemoptysis, dyspnea, pleuritic chest pain
โ€ข
20% ์ •๋„๋Š” extrapulmnoary manifestation > painless lymphadenopathy (m/c)

D. Diagnosis and differential diagnosis

CXR์€ ๊ฒฐํ•ต์˜ ์œ ์šฉํ•œ ์ง„๋‹จ๋ฐฉ๋ฒ•์ด์ง€๋งŒ(IA), ๋‹จ๋…์œผ๋กœ ๊ฒฐํ•ต์„ ์ง„๋‹จํ•˜์ง€ ์•Š๋Š”๋‹ค(ID).
CXR ์†Œ๊ฒฌ์ƒ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ๋ณ‘๋ณ€์ด ์žˆ์œผ๋ฉด ๊ฐ€๋Šฅํ•œ ๊ณผ๊ฑฐ ์‚ฌ์ง„๊ณผ ๋น„๊ตํ•ด ๋ณด์•„์•ผ ํ•œ๋‹ค(IIA).
CXR์—์„œ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋ฉด ๊ฐ๋‹ด ๊ฒฐํ•ต๊ท  ๊ฒ€์‚ฌ๋ฅผ ์‹ค์‹œํ•˜์—ฌย ํ™•์ง„ํ•˜๋„๋ก ๋…ธ๋ ฅํ•ด์•ผ ํ•œ๋‹ค(IIIA).
๋ฉด์—ญ์ƒํƒœ๊ฐ€ ์ •์ƒ์ธ ํ™˜์ž์—์„œ๋Š” ์ƒ์—ฝ์— ๊ณต๋™์„ ๋™๋ฐ˜ํ•˜๋Š” ํ˜•ํƒœ์˜ ํ๊ฒฐํ•ต์ด ์ฃผ๋กœ ๋ฐœ์ƒํ•˜๊ณ , ๋ฉด์—ญ์ €ํ•˜์ž์—์„œ๋Š” ํํ•˜์—ฝ์„ ์นจ๋ฒ”ํ•˜๋ฉฐ ๋ฆผํ”„์ ˆ์—ผ๊ณผ ํ‰๋ง‰์—ผ์„ ๋™๋ฐ˜ํ•˜๋Š” ํ๊ฒฐํ•ต์ด ์ฃผ๋กœ ๋ฐœ์ƒํ•œ๋‹ค.

D1. ๊ฒฐํ•ต์˜ ์ง„๋‹จ๊ณผ์ •

ํ˜ธํก๊ธฐ ์ฆ์ƒ์œผ๋กœ ๋‚ด์›ํ•œ ํ™˜์ž์˜ ์ž„์ƒ ์†Œ๊ฒฌ์ƒ ํ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋ฉด ๋จผ์ € ํ‰๋ถ€ X์„  ๊ฒ€์‚ฌ์™€ ๊ฐ๋‹ด ํ•ญ์‚ฐ๊ท  ๋„๋ง ๋ฐ ๋ฐฐ์–‘๊ฒ€์‚ฌ ๊ทธ๋ฆฌ๊ณ  ๊ฒฐํ•ต๊ท  ํ•ต์‚ฐ์ฆํญ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ ํ›„ ๊ทธ ๊ฒฐ๊ณผ๋ฅผ ๊ฐ€์ง€๊ณ  ํŒ์ •.
1. AFB ๋„๋ง (+), TB-PCR (+)
ํ๊ฒฐํ•ต์œผ๋กœ ์ง„๋‹จํ•˜๊ณ  ๊ฒฐํ•ต ์น˜๋ฃŒ์™€ ๊ฒฝ๊ณผ๋ฅผ ๊ด€์ฐฐํ•œ๋‹ค.
์žฌ์น˜๋ฃŒ ๋“ฑ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ Xpert MTB/RIF ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•˜๊ฑฐ๋‚˜, ๋„๋ง ์–‘์„ฑ ๊ฐ๋‹ด์„ ๋Œ€์ƒ์œผ๋กœ
๋ฆฌํŒœํ•€๊ณผ ์ด์†Œ๋‹ˆ์•„์ง€๋“œ์— ๋Œ€ํ•œ ์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค.
์ถ”ํ›„ ๋ฐฐ์–‘ ๊ฒ€์‚ฌ๊ฒฐ๊ณผ๋ฅผ ํ™•์ธํ•˜์—ฌ ๊ฒฐํ•ต๊ท ์ด ํ™•์ธ๋˜๋ฉด ์•ฝ์ œ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค.
2.ย AFB ๋„๋ง (+), TB-PCR (-)
NTM์œผ๋กœ ์ž ์ • ์ง„๋‹จํ•˜๊ณ  ์ถ”ํ›„ ๋น„๊ฒฐํ•ต ํ•ญ์‚ฐ๊ท  ๋ฐฐ์–‘์„ ํ™•์ธํ•˜๊ณ  ๊ท ๋™์ • ๊ฒ€์‚ฌย ์‹œํ–‰
3.ย AFB ๋„๋ง (-), TB-PCR (+)
ํ๊ฒฐํ•ต์œผ๋กœ ์ง„๋‹จํ•˜๊ณ  ๊ฒฐํ•ต ์น˜๋ฃŒ ํ›„ ๊ฒฝ๊ณผ๋ฅผ ๊ด€์ฐฐํ•œ๋‹ค.
์ถ”ํ›„ ๋ฐฐ์–‘ ๊ฒ€์‚ฌ๊ฒฐ๊ณผ๋ฅผ ํ™•์ธํ•˜์—ฌ ๊ฒฐํ•ต๊ท ์ด ํ™•์ธ๋˜๋ฉด ์•ฝ์ œ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค.
์žฌ์น˜๋ฃŒ ๋“ฑ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ ๋ฐฐ์–‘๋œ ๊ฒฐํ•ต๊ท ์ฃผ๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๋ฆฌํŒœํ•€ ๋˜๋Š” ๋ฆฌํŒœํ•€๊ณผ ์ด์†Œ๋‹ˆ์•„์ง€๋“œ์— ๋Œ€ํ•œ ์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค.
4.ย ย AFB ๋„๋ง (-), TB-PCR (-)
ํ™˜์ž์˜ ์ž„์ƒ์ฆ์ƒ ๋˜๋Š” ๋ฐฉ์‚ฌ์„ ํ•™์  ์†Œ๊ฒฌ์—์„œ ํ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜์ง€๋งŒ, ๊ฐ๋‹ด ๋„๋ง๊ฒ€์‚ฌ์™€ ๊ฒฐํ•ต๊ท  ํ•ต์‚ฐ์ฆํญ๊ฒ€์‚ฌ๊ฐ€ย ์Œ์„ฑ์ด๋ฉด์„œ, ํ•ญ๊ฒฐํ•ต ํšจ๊ณผ๊ฐ€ ์—†๋Š” ๊ด‘๋ฒ”์œ„ ํ•ญ์ƒ์ œ ์น˜๋ฃŒ์— ๋ฐ˜์‘์ด ์—†๊ณ , ์ง„๋ฃŒ์˜์‚ฌ๊ฐ€ ์ „๊ธฐ๊ฐ„์˜ ๊ฒฐํ•ต ์น˜๋ฃŒ๋ฅผ ์‹œํ–‰ํ•˜๊ธฐ๋กœ ๊ฒฐ์ •ํ•œ ๊ฒฝ์šฐ๋ฅผ ๋„๋ง ์Œ์„ฑ ํ๊ฒฐํ•ต์ด๋ผ ์ •์˜ํ•œ๋‹ค.
๋„๋ง ์Œ์„ฑ ํ๊ฒฐํ•ต์œผ๋กœ ์ง„๋‹จํ•˜์—ฌ ๊ฒฐํ•ต ์น˜๋ฃŒ ์ค‘์ธ ํ™˜์ž์—์„œย ๋ฐฐ์–‘ ๊ฒฐ๊ณผ๊ฐ€ ์–‘์„ฑ์ธ ๊ฒฝ์šฐ์—๋Š” ๊ฒฐํ•ต์œผ๋กœ ํ™•์ง„์ด ๊ฐ€๋Šฅํ•˜๋‹ค. ๊ทธ๋Ÿฌ๋‚˜, ๋ฐฐ์–‘๊ฒฐ๊ณผ๊ฐ€ ์Œ์„ฑ์ด๋”๋ผ๋„ ๊ฒฐํ•ต ์น˜๋ฃŒ๋กœย ์ž„์ƒย ์ฆ์ƒ ๋ฐ ๋ฐฉ์‚ฌ์„ ํ•™์  ์†Œ๊ฒฌ์ด ํ˜ธ์ „์„ ๋ณด์ด๋ฉด ์ง„๋ฃŒ์˜์‚ฌ๊ฐ€ ์ž„์ƒ์ ์œผ๋กœ ํŒ๋‹จํ•˜์—ฌ ๋ฐฐ์–‘ ์Œ์„ฑ ํ๊ฒฐํ•ต์œผ๋กœ ์ตœ์ข…์ ์œผ๋กœย ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
์ž„์ƒ์ฆ์ƒ ๋˜๋Š” ํ‰๋ถ€ X์„  ๊ฒ€์‚ฌ ์†Œ๊ฒฌ(๊ณผ๊ฑฐ ํ‰๋ถ€ X์„  ์‚ฌ์ง„๊ณผ ๋น„๊ต)์—์„œ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋‚˜ ํ•ญ์‚ฐ๊ท  ๋„๋ง ์Œ์„ฑ์ธ ๊ฒฝ์šฐ ๋‹ค์Œ๊ณผ ๊ฐ™์€ ๋ฐฉ๋ฒ•์œผ๋กœ ๋„๋ง ์Œ์„ฑ ํ๊ฒฐํ•ต์„ ์ง„๋‹จํ•œ๋‹ค.
ใ†ํ€ด๋†€๋ก ๊ณผ ์•„๋ฏธ๋…ธ๊ธ€๋ฆฌ์ฝ”์‹œ๋“œ ๋“ฑ์˜ ํ•ญ๊ฒฐํ•ต ํšจ๊ณผ๋ฅผ ๋ณด์ด๋Š” ํ•ญ์ƒ์ œ๋ฅผ ์ œ์™ธํ•œ ๊ด‘๋ฒ”์œ„ ํ•ญ์ƒ์ œ(broad-spectrum antibiotics)์— ๋Œ€ํ•œ ์น˜๋ฃŒ๋ฐ˜์‘์„ ์‚ดํŽด๋ณธ๋‹ค. ๊ด‘๋ฒ”์œ„ ํ•ญ์ƒ์ œ์— ๋ฐ˜์‘์ด ์žˆ์„ ๋•Œ์—๋Š” ๊ฒฐํ•ต์น˜๋ฃŒ๋ฅผ ํ•˜์ง€ ์•Š๊ณ  ๋ฐฐ์–‘๊ฒฐ๊ณผ๋ฅผ ๊ธฐ๋‹ค๋ฆฐ๋‹ค.
ใ†ํ‰๋ถ€ CT, ์œ ๋„๊ฐ๋‹ด ๊ฒ€์‚ฌ, ๊ธฐ๊ด€์ง€๋‚ด์‹œ๊ฒฝ ๊ฒ€์‚ฌ, ์กฐ์ง๊ฒ€์‚ฌ ๋“ฑ์„ ์‹œํ–‰ํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ ์ด๋Ÿฌํ•œ ๊ฒ€์‚ฌ์—์„œ ํ™œ๋™์„ฑ ๊ฒฐํ•ต์„ ์‹œ์‚ฌํ•˜๋Š” ์†Œ๊ฒฌ์ด ์žˆ์„ ๋•Œ ๋„๋ง ์Œ์„ฑ ํ๊ฒฐํ•ต์œผ๋กœ ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
ใ†์ถ”ํ›„ ๋ฐฐ์–‘ ๊ฒ€์‚ฌ๊ฒฐ๊ณผ๋ฅผ ํ™•์ธํ•˜์—ฌ ๊ฒฐํ•ต๊ท ์ด ๋ฐฐ์–‘๋˜๋ฉด ์•ฝ์ œ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค. ์žฌ์น˜๋ฃŒ ๋“ฑ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ ๋ฐฐ์–‘๋œ ๊ฒฐํ•ต๊ท ์ฃผ๋ฅผ ๋Œ€์ƒ์œผ๋กœ ๋ฆฌํŒœํ•€ ๋˜๋Š” ๋ฆฌํŒœํ•€๊ณผ ์ด์†Œ๋‹ˆ์•„์ง€๋“œ์— ๋Œ€ํ•œ ์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•œ๋‹ค.
โ€ข
Microscopy/culture
"acid-fast bacilli" : microscopic smear -sensitivity, specificity ๋†’์ง€ ์•Š๋‹ค.
cultrue: ํ™•์ง„, ์น˜๋ฃŒ๋ฒ• ๊ฒฐ์ •์— ์ค‘์š”ํ•˜์ง€๋งŒ ์‹œ๊ฐ„์ด ์˜ค๋ž˜ ๊ฑธ๋ฆผ
>ย Nucleic acid amplification test(NAAT): 1์ผ๋‚ด์— ๊ฒฐ๊ณผ, 95% sensitivity
smear(+)+NAAT(+)= treatment ์‹œ์ž‘, ํ•˜์ง€๋งŒ negative๋ผ๊ณ  ํ•ด์„œ r/o ํ•  ์ˆ˜๋Š” ์—†๋‹ค.
โ€ข
50์„ธ ์ด์ƒ์—์„œ๋Š” pnuemonia, respiratory complaint์—์„œ ์˜์‹ฌํ•ด์•ผ ํ•˜๋ฉฐ HIV ๋˜๋Š” ๋ฉด์—ญ์ €ํ•˜์ž์—์„œ๋„ ๋‹ค์–‘ํ•œ ์ฆ์ƒ ๋ณด์ผ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ์‘๊ธ‰์‹ค์—์„œ ์˜์‹ฌํ•˜๊ณ  culture ์‹œํ–‰, ์ „์—ผ์— ์ฃผ์˜ํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”

D2. Microscopy/culture

(1) ํ•ญ์‚ฐ๊ท  ๋„๋ง๊ฒ€์‚ฌ (AFB Stain)

.ย ํ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ํ™˜์ž๋Š” ๊ฐ๋‹ด์„ ์ตœ์†Œํ•œ 2ํšŒ, ๊ฐ€๋Šฅํ•œ 3ํšŒ ์ฑ„์ทจํ•˜์—ฌ ํ•ญ์‚ฐ๊ท  ๋„๋ง ๋ฐ ๋ฐฐ์–‘๊ฒ€์‚ฌ๋ฅผ
์‹œํ–‰ํ•ด์•ผ ํ•œ๋‹ค(IA).
.ย ํ•ญ์‚ฐ๊ท  ๋„๋ง๊ฒ€์‚ฌ๋Š” ๊ฐ€๋Šฅํ•œ ๋นจ๋ฆฌ ์‹œํ–‰ํ•˜๊ณ , ๋„๋ง ์–‘์„ฑ ๊ฒฐ๊ณผ๋Š” 24์‹œ๊ฐ„ ์ด๋‚ด์— ํ†ต๋ณดํ•ด์•ผ ํ•œ๋‹ค(IIIA).
๋„๋ง๊ฒ€์‚ฌ๋Š” ๊ฒฐํ•ต๊ท ๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ๋น„๊ฒฐํ•ต ํ•ญ์‚ฐ๊ท (nontuberculous mycobacteria, NTM)๋„ ์–‘์„ฑ์œผ๋กœ ๋‚˜์˜ฌ ์ˆ˜ ์žˆ์œผ๋ฏ€๋กœ ๋„
์–‘์„ฑ์ด์ง€๋งŒ ๊ฒฐํ•ต๊ท  PCR ๊ฒ€์‚ฌ๊ฐ€ ์Œ์„ฑ์ธ ๊ฒฝ์šฐ๋Š” ๋น„๊ฒฐํ•ตํ•ญ์‚ฐ๊ท ์„ ์˜์‹ฌํ•ด์•ผ ํ•œ๋‹ค.
โ€ข
์ฃผ๋กœ sputum (๋•Œ๋กœ๋Š” gastric aspirates, pleural and other body fluids)
โ€ข
Microscopic smear, sensitivity์™€ specificity ๋†’์ง€ ์•Š๋‹ค.

(2) ํ•ญ์‚ฐ๊ท  ๋ฐฐ์–‘๊ฒ€์‚ฌ (AFB stain & culture)

โ€ข
๊ฒฐํ•ต๊ท ๊ฒ€์‚ฌ๋ฅผ ์œ„ํ•ด ์˜๋ขฐ๋œ ๊ฒ€์ฒด๋Š” ํ•ญ์‚ฐ๊ท  ๋„๋ง ๋ฐ ๋ฐฐ์–‘๊ฒ€์‚ฌ๋ฅผ ๋™์‹œ์— ์‹œํ–‰ํ•ด์•ผ ํ•œ๋‹ค(IA).
โ€ข
๊ฒ€์ฒด๋Š” ๊ณ ์ฒด๋ฐฐ์ง€์™€ ์•ก์ฒด๋ฐฐ์ง€์— ๊ฐ๊ฐ ์ ‘์ข…ํ•ด์•ผ ํ•œ๋‹ค(IIA). ๊ณ ์ฒด๋ฐฐ์ง€ 3-8์ฃผ ์•ก์ฒด๋ฐฐ์ง€ 2์ฃผ
โ€ข
ํ•ญ์‚ฐ๊ท  ์ฆ์‹์ด ํ™•์ธ๋˜๋ฉด ์‹ ์†ํ•˜๊ฒŒ ๊ฒฐํ•ต๊ท ๊ณผ ๋น„๊ฒฐํ•ต ํ•ญ์‚ฐ๊ท  ๊ฐ๋ณ„๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•˜์—ฌ ๊ฒฐ๊ณผ๋ฅผ ํ†ต๋ณดํ•ด์•ผ ํ•œ๋‹ค(IIIA).

(3) ๊ฒฐํ•ต๊ท  ํ•ต์‚ฐ์ฆํญ๊ฒ€์‚ฌ (TB/NTM PCR)

โ€ข
๊ฒฐํ•ต์ด ์˜์‹ฌ๋  ๋•Œ ๋„๋ง ๋ฐ ๋ฐฐ์–‘ ๊ฒ€์‚ฌ์™€ ํ•จ๊ป˜ ๊ฒฐํ•ต๊ท  ํ•ต์‚ฐ์ฆํญ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•ด์•ผ ํ•œ๋‹ค(IIIA).
โ€ข
ํŠน์ด๋„๊ฐ€ ๋งค์šฐ ๋†’์€ ๊ฒ€์‚ฌ, ๋„๋ง๊ฒ€์‚ฌ๋ณด๋‹ค๋Š” ๋†’์€ ๋ฏผ๊ฐ๋„
โ€ข
๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ๋ชจ๋“  ํ™˜์ž์—์„œ ์‹œํ–‰ํ•ด์•ผ ํ•จ
โ€ข
๋„๋ง๊ฒ€์‚ฌ ์Œ์„ฑ, PCR ์–‘์„ฑ์ด๋ฉด ๊ฒฐํ•ต์ง„๋‹จ์ด ๊ฐ€๋Šฅํ•˜๋‚˜, PCR ์Œ์„ฑ์ด๋ผ๋„ ๋ฐฐ์ œ๋Š” ์•ˆ ๋จ
โ€ข
1์ผ ๋‚ด ๊ฒฐ๊ณผ
โ€ข
Detect as few as 1 to 10 organisms/mL sample.
โ€ข
AFB stain๋ณด๋‹ค sensitivity๊ฐ€ ์ข‹์Œ. smear(+) ์ธ ํ™˜์ž์—๊ฒŒ์„œ 90~95% sensitivity.
โ€ข
AFB (+) and NAAT (+) โ†’ Treatment ๋ฐ”๋กœ ์‹œ์ž‘ (culture ๊ฒฐ๊ณผ๊ฐ€ ๋‹น์žฅ ์—†์–ด๋„)

(4) Sputum or other tissue culture

โ€ข
ํ™•์ง„์˜ ๊ฐ€์žฅ ์ข‹์€ ๋ฐฉ๋ฒ•
โ€ข
Confirming infection and drug susceptibility
โ€ข
์‹œ๊ฐ„์ด ์˜ค๋ž˜ ๊ฑธ๋ฆฐ๋‹ค๋Š” ๋‹จ์ 

(4) ์•ฝ์ œ ๊ฐ์ˆ˜์„ฑ ๊ฒ€์‚ฌ (MTB drug sensitivity (๊ท ์ฃผ))

โ€ข
์ „ํ†ต์  ๊ฒ€์‚ฌ
โ—ฆ
๋ชจ๋“  ๊ฒฐํ•ตํ™˜์ž์˜ ์ฒซ ๋ฐฐ์–‘๊ท ์ฃผ์— ๋Œ€ํ•ด ํ•ญ๊ฒฐํ•ต์ œ์— ๋Œ€ํ•œ ์•ฝ์ œ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹ค์‹œํ•ด์•ผ ํ•œ๋‹ค(IA).
โ—ฆ
3๊ฐœ์›” ์ด์ƒ ์น˜๋ฃŒ์—๋„ ๋ฐฐ์–‘ ์–‘์„ฑ์ด๊ฑฐ๋‚˜ ์ž„์ƒ์ ์œผ๋กœ ์น˜๋ฃŒ์‹คํŒจ๊ฐ€ ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ์— ์•ฝ์ œ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ๋ฅผ ๋‹ค์‹œ ์‹œํ–‰ํ•ด์•ผ ํ•œ๋‹ค(IA).
โ—ฆ
์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ, Xpert MTB/RIF ํ˜น์€ ์•ก์ฒด๋ฐฐ์ง€ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ์—์„œ ์•ฝ์ œ ๋‚ด์„ฑ์ด ๊ฒ€์ถœ๋œ ๊ฒฝ์šฐ ์ฃผ์š” ์ผ์ฐจ, ์ด์ฐจ ํ•ญ๊ฒฐํ•ต์ œ์— ๋Œ€ํ•œ ๊ฐ์ˆ˜์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•˜์—ฌ์•ผ ํ•œ๋‹ค(IIIA).
โ€ข
์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ
โ—ฆ
์žฌ์น˜๋ฃŒ ๋“ฑ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜๋Š” ๊ฒฝ์šฐ ๋„๋ง ์–‘์„ฑ ๊ฒ€์ฒด ํ˜น์€ ๋ฐฐ์–‘๋œ ๊ฒฐํ•ต๊ท ์ฃผ๋ฅผ ๋Œ€์ƒ์œผ๋กœ Rifampin๊ณผ INH์— ๋Œ€ํ•œ ์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•ด์•ผ ํ•œ๋‹ค(IA).
โ—ฆ
๊ทธ ์™ธ ์ƒํ™ฉ์—์„œ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์„ ๊ฒ€์ถœํ•˜๊ธฐ ์œ„ํ•ด ์‹ ์†๋‚ด์„ฑ๊ฒ€์‚ฌ๋ฅผ ์ดˆ๊ธฐ ๊ฒ€์‚ฌ๋กœ ์‹œํ–‰ํ•  ์ˆ˜ ์žˆ๋‹ค(IIB).

D3. ์กฐ์งํ•™์  ์ง„๋‹จ

D4. ๊ธฐํƒ€๊ฒ€์‚ฌ

(1) CXR
โ€ข
๋„๋ง์Œ์„ฑ ํ๊ฒฐํ•ต์˜ ๊ฒฝ์šฐ ํ‰๋ถ€ X์„  ๊ฒ€์‚ฌ๋กœ ํ™œ๋™์„ฑ ์—ฌ๋ถ€๋ฅผ ํŒ๋‹จํ•˜๊ธฐ ์–ด๋ ค์šธ ๋•Œ ํ‰๋ถ€ ์ „์‚ฐํ™” ๋‹จ์ธต์ดฌ์˜์„ ๊ณ ๋ คํ•œ๋‹ค(IIIB).
โ€ข
๊ฒฐํ•ต๊ณผ ๋‹ค๋ฅธ ์›์ธ์งˆํ™˜์˜ ๊ฐ๋ณ„์ด ์–ด๋ ค์šธ ๊ฒฝ์šฐ ํ‰๋ถ€ ์ „์‚ฐํ™” ๋‹จ์ธต์ดฌ์˜์„ ๊ณ ๋ คํ•œ๋‹ค(IIIB).
โ€ข
primary infection: lung ์–ด๋””์—์„œ๋“  parenchymal infiltrates ๋ฐœ๊ฒฌ ๋  ์ˆ˜ ์žˆ๋‹ค. ๋‹ค์–‘ํ•œ ํ˜•ํƒœ๋กœ ๋‚˜ํƒ€๋‚˜๊ธฐ ๋•Œ๋ฌธ์— ์ด์ „๊ณผ ๋น„๊ตํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”
โ€ข
latent tuberculosis: upper lobe, hilar nodule, fibrotic lesion, bronchiectasis, volume loss, pleural scarring ๋“ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๊ณ  Ghon foci ๋ณด์ผ ์ˆ˜ ์žˆ๋‹ค.
โ€ข
Reactivation infection: classic findings - ๊ณต๋™์„ฑ/๋น„๊ณต๋™์„ฑ ๋ณ‘๋ณ€(cavitary/noncavitary lesion)์ด ํ์ƒ์—ฝ, ๋˜๋Š” ํํ•˜์—ฝ์˜ ์ƒ๋ถ€์—์„œ ๋ณด์ž„
โ€ข
๋ฉด์—ญ์ €ํ•˜ ํ™˜์ž, HIV ํ™˜์ž์—์„œ๋„ ๋ฉด์—ญ ๋–จ์–ด์ง„ ๊ฒฝ์šฐ์—์„œ ์ „ํ˜•์ ์ธ chest finding ๋งŽ๋‹ค.

D5. ๋ฉด์—ญํ•™์  ์ง„๋‹จ

โ€ข
๊ฒฐํ•ต๊ฐ์—ผ๊ฒ€์‚ฌ์ธ ํˆฌ๋ฒ ๋ฅด์ฟจ๋ฆฐ ๊ฒ€์‚ฌ(์ผ๋ฐ˜ํ™˜์ž TB skin test, ํ”ผ๋ถ€๋ฐ˜์‘๊ฒ€์‚ฌ-๊ฒฐํ•ต)์™€ IGRA (์ผ๋ฐ˜ํ™˜์ž IGRA plus) ๋Š” ํ™œ๋™์„ฑ ๊ฒฐํ•ต๊ณผ ์ž ๋ณต๊ฒฐํ•ต๊ฐ์—ผ์„ ๊ตฌ๋ณ„ํ•  ์ˆ˜ ์—†์œผ๋ฏ€๋กœ ํ™œ๋™์„ฑ ๊ฒฐํ•ต์˜ ์ง„๋‹จ์„ ์œ„ํ•ด ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์€ ๊ถŒ๊ณ ํ•˜์ง€ ์•Š๋Š”๋‹ค(ID).
โ€ข
ํ์™ธ๊ฒฐํ•ต๊ณผ ๊ฐ™์ด ์ž„์ƒ์ ์œผ๋กœ ๊ฒฐํ•ต์ด ์˜์‹ฌ๋˜์ง€๋งŒ ๊ฒฐํ•ต๊ท  ๊ฒ€์‚ฌ๊ฐ€ ์Œ์„ฑ์ด๊ณ  ์ง„๋‹จ์ด ์–ด๋ ค์šด ๊ฒฝ์šฐย ๊ฒฐํ•ต๊ท  ๊ฐ์—ผ ๊ฒ€์‚ฌ๊ฐ€ ํ™œ๋™์„ฑ ๊ฒฐํ•ต์˜ ์ง„๋‹จ์„ ์œ„ํ•ด ๋ณด์กฐ์ ์œผ๋กœ ์‚ฌ์šฉ๋  ์ˆ˜ ์žˆ๋‹ค(IB).

(1) Mantoux or Tuberculin skin test : m/c screening test

โ€ข
๋ฏผ๊ฐ๋„ 70%, ํŠน์ด๋„ 59%
โ€ข
Purified protein derivative(PPD) 0.1ml ์ „์™„๋ถ€ ์ฃผ์ž…
โ€ข
์ด์ „ ๋…ธ์ถœ์ด๋‚˜ ๊ฐ์—ผ์— ์˜ํ•œ delayed-type hypersensitivity reaction โ†’ 48~72์‹œ๊ฐ„ ํ›„ skin induration ํ‰๊ฐ€ (erythema๋‚˜ ๋‹ค๋ฅธ skin change๋Š” ์•„๋‹˜)
โ€ข
BCG ์ ‘์ข…, NTM ๋…ธ์ถœ : ๊ฐ์—ผ ์—†์–ด๋„ positive ๊ฒฐ๊ณผ ๋‚˜์˜ฌ ์ˆ˜ ์žˆ์Œ.
โ€ข
๋Œ€ํ•œ ๊ฒฐํ•ตํ˜‘ํšŒ์—์„œ๋Š” 10 mm ์ด์ƒ๋ถ€ํ„ฐ ์–‘์„ฑ์œผ๋กœ ํŒ์ • (์šฐ๋ฆฌ๋‚˜๋ผ๋Š” BCG ์ ‘์ข…๋ฅ ์ด ๋†’์•„์„œ)

(2) interferon-gamma release assys (IGRA)

โ€ข
M. tuberculosis์— ์กด์žฌํ•˜๋Š” protein peptide์˜ ๋ฐ˜์‘์„ ๋ณด๋Š” ๊ฒ€์‚ฌ
โ€ข
BCG vaccine์ด๋‚˜ NTM์— ์˜ํ–ฅ ์—†์–ด์„œ skin test๋ณด๋‹ค more specific test. (๋ฏผ๊ฐ๋„ 84%, ํŠน์ด๋„ 99%)
โ€ข
Latent Tb์— ๋Œ€ํ•ด 95% ์ด์ƒ์˜ specificity, 90%์˜ sensitivity.
โ€ข
History, chest radiograph, culture ๋“ฑ์„ ์ข…ํ•ฉํ•ด๋ณผ ๋•Œ active tb๊ฐ€ ์˜์‹ฌ๋˜๋ฉด ์‹œํ–‰
โ€ข
๊ฒฐ๊ณผ๊นŒ์ง€ 16~24์‹œ๊ฐ„ ํ•„์š” (positive, negative, indeterminant)
โ€ข
๋…ธ์ˆ™์ž๋‚˜ ์•ฝ๋ฌผ ์ค‘๋…์ž ๊ฐ™์€ follow-up care๊ฐ€ ํž˜๋“  ๊ฒฝ์šฐ์— ์œ ์šฉ
โ€ข
Skin test์— ์œ„์–‘์„ฑ์„ ๋ณด์ผ ์ˆ˜ ์žˆ๋Š” ํ™˜์ž๊ตฐ์ด๋‚˜ ๋…ธ์ถœ๋œ ์ด๋ ฅ์ด ์žˆ๋Š” healthcare worker ๋“ฑ ์œ ์šฉ
โ€ข
Latent, active Tb๋ฅผ ๊ตฌ๋ณ„ํ•  ์ˆ˜ ์—†์œผ๋ฉฐ, ๋ฉด์—ญ์ €ํ•˜ ํ™˜์ž๋“ค์—๊ฒŒ ์œ„์Œ์„ฑ์ด ๋‚˜์˜ฌ ์ˆ˜ ์žˆ๋‹ค.

D6. Chest radiograph

(1) Primary tuberculosis โ‘  Lung ์–ด๋””์—์„œ๋“  parenchymal infiltrates ๋ฐœ๊ฒฌ๋  ์ˆ˜ ์žˆ๋‹ค. โ‘ก Isolated ipsilateral hilar, mediastinal adenopathym calcified lymph nodes, unilateral pleural effusions ๋“ฑ ๋‹ค์–‘ํ•œ ํ˜•ํƒœ๋กœ ๋‚˜ํƒ€๋‚˜๊ธฐ ๋•Œ๋ฌธ์— ์ด์ „๊ณผ ๋น„๊ตํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š” (2) Latent tuberculosis โ‘  Upper lobe or hilar nodules, fibrotic lesions, calcified lesions, bronchiectasis, volume loss, pleural scarring ๋“ฑ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ๋‹ค. โ‘ก Healed primary infection area๋Š” Ghon foci๋กœ ๔€Ÿฟ์ผ ์ˆ˜ ์žˆ๋‹ค. (3) Reactivation infection โ‘  Classic findings : Cavitary/noncavitary lesion์ด ํ์ƒ์—ฝ, ๋˜๋Š” ํํ•˜์—ฝ์˜ ์ƒ๋ถ€์—์„œ ๔€Ÿฟ์ž„ (either bilateral or unilateral) (4) Radiograph์˜ finding์€ Tb์˜ stage๔€Ÿฟ๋‹ค immune system์˜ ์ •๋„์— ๋”ฐ๋ผ ๋ชจ์Šต์ด ๊ฒฐ์ •๋  ์ˆ˜ ์žˆ๋‹ค. โ‘  ์ •์ƒ ๋ฉด์—ญ ํ™˜์ž์˜ ๊ฒฝ์šฐ classic finding์„ ๔€Ÿฟ์ด๋‚˜, HIV๋“ฑ ๋ฉด์—ญ์ €ํ•˜ ํ™˜์ž์—๊ฒŒ์„œ atypical finding์ด ๋” ๋งŽ์ด ๋‚˜ํƒ€๋‚จ.
โ‘ก Advanced HIV ํ™˜์ž 22% ์ •๋„์—์„œ๋Š” X-ray๊ฐ€ ์ •์ƒ์ด๋‹ค. ๊ทธ๋ ‡๊ธฐ ๋•Œ๋ฌธ์— ๋ฉด์—ญ์ €ํ•˜์ž์—๊ฒŒ๋Š” CT๊ฐ€ ๋” sensitive ํ•  ์ˆ˜ ์žˆ๋‹ค.

D7. Xpert MTB/RIF (MTB/RIF resistance PCR)

โ€ข
PCR ๊ธฐ๋ฒ•์„ ์‚ฌ์šฉํ•˜์—ฌ ์ถ”์ถœ,์ฆํญ,ํŒ์ •๊นŒ์ง€ ํ•œ ๋ฒˆ์—.
โ€ข
๋ฆฌํŒœํ•€ ๋‚ด์„ฑ๊นŒ์ง€ ํŒ์ •.
โ€ข
๋ฆฌํŒœํ•€ ๋‚ด์„ฑ์ด ๋‹ค์ œ๋‚ด์„ฑ์„ ์˜๋ฏธํ•˜์ง€๋Š” ์•Š์ง€๋งŒ, ๋ฆฌํŒœํ•€ ๋‹จ๋…๋‚ด์„ฑ์€ ๋“œ๋ฌผ๋‹ค.
โ€ข
์žฌ์น˜๋ฃŒ์™€ ๊ฐ™์ด ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์˜ ๊ฐ€๋Šฅ์„ฑ์ด ๋†’์€ ๊ฒฝ์šฐ ์ดˆ๊ธฐ์ง„๋‹จ ๊ฒ€์‚ฌ๋กœ Xpert MTB/RIF๋ฅผ ์‹œํ–‰ํ• ย ์ˆ˜ ์žˆ๋‹ค(IA).
โ€ข
์ค‘์ฆ๊ฒฐํ•ต์ด๋‚˜ HIV ๊ฐ์—ผ์ธ์—์„œ ๋ฐœ์ƒํ•œ ๊ฒฐํ•ต์ฒ˜๋Ÿผ ์•ฝ์ œ๋‚ด์„ฑ์—ฌ๋ถ€๋ฅผ ์‹ ์†ํ•˜๊ฒŒ ํ™•์ธํ•ด์•ผ ํ•˜๋Š” ๊ฒฝ์šฐย Xpert MTB/RIF ๊ฒ€์‚ฌ๋ฅผ ์‹œํ–‰ํ•  ์ˆ˜ ์žˆ๋‹ค(IA).
โ€ข
๊ทธ ์™ธ ์ƒํ™ฉ์—์„œ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต์„ ๊ฒ€์ถœํ•˜๊ธฐ ์œ„ํ•ด Xpert MTB/RIF ๊ฒ€์‚ฌ๋ฅผ ์ดˆ๊ธฐ ๊ฒ€์‚ฌ๋กœ ์‹œํ–‰ํ• ย ์ˆ˜ ์žˆ๋‹ค (IIB).
โ€ข
๋ฆฌํŒœํ•€ ๋‚ด์„ฑ ๊ฐ€๋Šฅ์„ฑ์ด ๋‚ฎ์€ ์ƒํ™ฉ์—์„œ ๋‚ด์„ฑ์œผ๋กœ ๋‚˜์˜ค๋ฉด ์žฌ๊ฒ€์„ ์‹œํ–‰ํ•˜๊ฑฐ๋‚˜ ๋‹ค๋ฅธ ๊ฐ์ˆ˜์„ฑ ๊ฒ€์‚ฌ๋ฒ•์œผ๋กœ ํ™•์ธํ•œ๋‹ค(IIB).
โ€ข
์‹ ์†ํ•œ ๊ฒฐํ•ต์ง„๋‹จ์„ ์œ„ํ•ด์„œ ์ดˆ๊ธฐ ๊ฒ€์‚ฌ๋กœ Xpert MTB/RIF๋ฅผ ์‹œํ–‰ํ•  ์ˆ˜ ์žˆ๋‹ค(IIB).
โ€ข
์šฐ๋ฆฌ๋‚˜๋ผ์˜ ๊ฒฝ์šฐ ๊ฒ€์‚ฌ์‹ค ์ธํ”„๋ผ๊ฐ€ ์ž˜ ๊ฐ–์ถฐ์ ธ ์žˆ์ง€๋งŒ ์—ญํ•™์กฐ์‚ฌ๋‚˜ ํ™˜์ž๊ฒฉ๋ฆฌ ์—ฌ๋ถ€๋ฅผ ๋นจ๋ฆฌ ๊ฒฐ์ •ํ•ด์•ผ ํ•˜๋Š” ์ƒํ™ฉ์—์„œ Xpert๊ฐ€ ๋„์›€์ด ๋  ์ˆ˜ ์žˆ๋‹ค.

E. Treatment

โ€ข
์น˜๋ฃŒ ์ „ ์ฃผ์˜์‚ฌํ•ญ : ์ž„์˜๋กœ ์ค‘๋‹จ ์‹œ ๋‹ค์ œ๋‚ด์„ฑ ๊ฒฐํ•ต ์šฐ๋ ค. ๋‹ค์ œ๋‚ด์„ฑ ์‹œ ์น˜๋ฃŒ๊ธฐ๊ฐ„ 18~24๊ฐœ์›” ์†Œ์š”, ์„ฑ๊ณต๋ฅ ๋„ 50~60%๋กœ ์ €ํ•˜๋˜๋ฏ€๋กœ, ์ดˆ๊ธฐ ์น˜๋ฃŒ์— ์ ๊ทน์ ์ธ ์•ฝ๋ฌผ๋ณต์šฉ์œผ๋กœ ์™„์น˜ํ•˜๋Š” ๊ฒƒ์ด ์ค‘์š”ํ•จ.
โ€ข
์›์น™ : ์ตœ์†Œ 3์ข… ์ด์ƒ ๋ณ‘ํ•ฉ์š”๋ฒ•, 6๊ฐœ์›” ์ด์ƒ๋ณต์šฉ, ํ•˜๋ฃจ 1ํšŒ ํˆฌ์•ฝ, ๊ณต๋ณต ํˆฌ์—ฌ

E1. Active tuberculosis

(1) First line medications : 4์ œ ์š”๋ฒ• (INH, RIF, PZA, ethambutol) 8์ฃผ

โ€ข
2HERZ + 4HER/9HER (์ž„์‹  ์‹œ)
โ€ข
Second line medications : Drug-resistant case, side effect ์žˆ๋Š” ๊ฒฝ์šฐ โ†’ Fluoroquinolone์„ ํฌํ•จํ•œ ์•ฝ์ œ ์กฐํ•ฉ
โ€ข
CDC regimen (1) ๋งค์ผ 4์ œ ์š”๋ฒ• (INH, RIF, PZA, ethambutol) 8์ฃผ + 2์ œ (INF/RIF or INF/rifapentine) 18์ฃผ (2) ๋งค์ผ 4์ œ ์š”๋ฒ• 2์ฃผ + ์ฃผ๋‹น 2ํšŒ 6์ฃผ + INH/RIF ๋˜๋Š” INH/rifapentine 18์ฃผ (3) 4์ œ ์š”๋ฒ• ์ฃผ๋‹น 3ํšŒ 8์ฃผ + INH/RIF ์ฃผ๋‹น 3ํšŒ 18์ฃผ (4) ๋งค์ผ 3์ œ ์š”๋ฒ• (INH, RIF, ethambutol) 8์ฃผ+ INH/RIF 31์ฃผ
โ€ข
์ฒ˜๋ฐฉ๋ก€. 6๊ฐœ์›” ๋‹จ๊ธฐ์š”๋ฒ• : 2 HERZ + 4HER ์œ ํ•œ์ง“์ • 100 mg 3T # 1 PO ๋ฆฌํŒœํ•€์ • 600 mg 1T #1 PO ํƒ๋ถ€ํ†จ์ • 400 mg 3T #1 PO ํ”ผ๋ผ์ง„์•„๋ฏธ๋“œ์ • 500 mg 3T #1 PO + ํ”ผ๋ฆฌ๋…์‹  (B6)

(2) ์žฌ์น˜๋ฃŒ : ๋ชจ๋“  ๊ฒฝ์šฐ ๋ฐ˜๋“œ์‹œ ์•ฝ์ œ๊ฐ์ˆ˜์„ฑ ๊ฒ€์‚ฌ

ํ•ญ๊ฒฐํ•ต์ œ
ํˆฌ์—ฌ๋ฐฉ๋ฒ•
์ฃผ์š”๋ถ€์ž‘์šฉ
์น˜๋ฃŒ์‹คํŒจ
์น˜๋ฃŒ์‹œ์ž‘ ํ›„ 3๊ฐœ์›” ํ›„ ๊ฐ๋‹ด๋ฐฐ์–‘ or AFB ์–‘์„ฑ ์ž„์ƒ์ฆ์ƒ ๊ฐœ์„  ์•ˆ ๋จ
์•ฝ์ œ ๋ชจ๋‘ ๋ฐ”๊ตฌ์–ด 3์ œ ์ด์ƒ ์‚ฌ์šฉ โ†’ ,E, R ์ดˆํ•จ ์‹œ 1๋…„ ์น˜๋ฃŒ โ†’ ๊ทธ ์™ธ 1.5๋…„ ์น˜๋ฃŒ
์žฌ๋ฐœ
๋‹จ๊ธฐ์š”๋ฒ• ํ›„ ๊ท  ์Œ์„ฑ ๋˜์–ด ์ข…๊ฒฐํ•œ ๋’ค ๋‹ค์‹œ ๋ฐฐ์ถœ๋˜๋Š” ๊ฒฝ์šฐ
์ด์ „ ์•ฝ์ œ ๊ณ„์†์‚ฌ์šฉ ์ดˆ์น˜๋ฃŒ๊ธฐ๊ฐ„ + 3๊ฐœ์›” ์—ฐ์žฅ
์กฐ๊ธฐ์ค‘๋‹จ
์น˜๋ฃŒ๊ธฐ๊ฐ„ ๋ถˆ์ถฉ๋ถ„ํ•จ
์“ฐ๋˜ ์•ฝ์ œ๋กœ 18๊ฐœ์›” ์ด์ƒ ์น˜๋ฃŒ

(3) ์ผ๋ถ€ ํ™˜์ž์—์„œ tuberculosis ์น˜๋ฃŒ๋ฅผ ์‹œ์ž‘ํ•˜๊ณ  ๋‚˜์„œ ์ž„์ƒ์–‘์ƒ์˜ ์•…ํ™”๋ฅผ ๋ณด์ด๋Š” ๊ฒฝ์šฐ

โ†’ Paradoxical reaction, immune reconstitution syndrome Fever / Respiratory status ์•…ํ™” / Lymphadenopathy / Hepatosplenomegaly Ascites / Meningitis / CNS lesion ์•…ํ™” / Hypercalcemia (unique finding) ์ฆ์ƒ ์‹ค์ œ๋กœ๋Š” ๋ฉด์—ญ์ƒํƒœ ํ˜ธ์ „ (Mycobacteria ๋Œ€ํ•œ ๋ฉด์—ญ๋ฐ˜์‘์˜ ๊ฒฐ๊ณผ์ด๋‚˜ ์น˜๋ฃŒ ์‹คํŒจ, ์•ฝ์ œ ๋‚ด์„ฑ๊ณผ ๊ตฌ๋ถ„ ์–ด๋ ค์›€)

E2. Latent tuberculosis

(1) Recent asymptomatic skin test conversion ํ™•์ธ๋œ ๊ฒฝ์šฐ (2) Active infected patient์™€ close contact๊ฐ€ ์žˆ๋Š” ๊ฒฝ์šฐ โ†’ Anergic patients with known tuberculosis contact์—์„œ ์น˜๋ฃŒ

E3. ํ•ญ๊ฒฐํ•ต์ œ ๋ถ€์ž‘์šฉ์— ๋Œ€ํ•œ ๋Œ€์ฒ˜

(1) ์ฃผ์š” ๋ถ€์ž‘์šฉ์— ๋Œ€ํ•œ ๋Œ€์ฒ˜
์œ„์žฅ๊ด€์žฅ์• 
์‹ํ›„ 30๋ถ„ ๋ณต์šฉ, ์ทจ์นจ ์ „ ๋ณต์šฉ, ์•„์นจ/์ €๋… ๋ถ„๋ณต์œผ๋กœ ๋ณ€๊ฒฝ ๊ณ ๋ ค
๊ฐ„๋…์„ฑ
INH, RIF, PZN ๊ฐ€ ํ”ํ•œ ์›์ธ์•ฝ์ œ 1. AST/ALT ๊ฐ€ ์ •์ƒ์˜ 5๋ฐฐ ์ด์ƒ ์ฆ๊ฐ€ ์‹œ 2. ํ™ฉ๋‹ฌ+AST/ALT๊ฐ€ ์ •์ƒ์˜ 3๋ฐฐ 3. ๋งŒ์„ฑ๊ฐ„์—ผ ํ™˜์ž์˜ ๊ฒฝ์šฐ ํ‰์†Œ ์ˆ˜์น˜์˜ 3~5๋ฐฐ ์ฆ๊ฐ€ ์‹œ โ†’ ๊ฒฐํ•ต์•ฝ ์ค‘๋‹จ - ์žฌํˆฌ์—ฌ : ALT๊ฐ€ ์ •์ƒ ์ƒํ•œ์น˜์˜ 2๋ฐฐ ์ด๋ผํ˜ธ ๊ฐ์†Œ ์‹œ ํ•œ ๊ฐ€์ง€์”ฉ ํˆฌ์—ฌ - RIF 150 mg โ†’ RIF 450/600 mg โ†’ INH 100 mg โ†’ INH 300 mg ์ˆœ์œผ๋กœ ํˆฌ์—ฌ - ์ƒ๊ธฐ ์•ฝ์ œ๊ฐ€ ์„ฑ๊ณต์ ์„ ํˆฌ์—ฌ๋˜๋ฉด PZN์— ์œ„ํ•œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผํ•˜๊ณ  PZN๋Š” ์žฌํˆฌ์—ฌ ํ•˜์ง€ ์•Š๋Š”๋‹ค.
๊ด€์ ˆํ†ต์ฆ
- ํ†ตํ’ ๋ฐœ์ƒ ์‹œ์—๋Š” ์ค‘๋‹จ - PZA์— ์ดํ•œ ๊ด€์ฒ ํ†ต์€ ์†Œ์—ผ์ œ ํˆฌ์—ฌํ•˜๋ฉด์„œ ๊ด€์ฐฐ
ํ”ผ๋ถ€ ๋ถ€์ž‘์šฉ
์ ์ƒ ์ถœํ˜ˆ ์‹œ PLT ๊ฐ์†Œ์ผ ์ˆ˜ ์žˆ์–ด CBC ํ™•์ธ ๋ฐœ์—ด๊ณผ ์ ๋ง‰ ์นจ๋ฒ”์ด ๋™๋ฐ˜๋˜๋Š” ๊ฒฝ์šฐ ์Šคํ‹ฐ๋ธ ์กด์Šจ ๊ฐ€๋Šฅ์„ฑ์ด ์žˆ์œผ๋ฏ€๋กœ ๋ชจ๋“  ์•ฝ์ œ ์ค‘๋‹จ

F. Disposition

F1. OPD

1) ๋Œ€๋ถ€๋ถ„์˜ ํ™˜์ž (2) Antituberculosis medication์€ consultant, f/u provider๊ฐ€ ๋™์˜ํ•˜๋Š” ๊ฒฝ์šฐ ์™ธ์—๋Š” ED์—์„œ ์‹œ์ž‘ํ•˜์ง€ ์•Š์Œ.

F2. ์ž…์›

(1) Ill-appearing (2) Hypoxemic (3) Dyspneic, (4) Uncertain diagnosis (5) Non compliance (6) Drug resistant (7) social situation์ด ์น˜๋ฃŒ์— ๋ฐฉํ•ด๊ฐ€ ๋˜๋Š” ๊ฒฝ์šฐ

G. Special population

G1. HIV

โ€ข
Tb์˜ ์ž˜ ์•Œ๋ ค์ง„ risk factor
โ€ข
์ข…์ข… ๋ฉด์—ญ์ €ํ•˜์˜ ์ฒ˜์Œ ์ฆ์ƒ์œผ๋กœ ๋‚˜ํƒ€๋‚  ์ˆ˜ ์žˆ์œผ๋ฉฐ ๋ฐœ๋ณ‘ ์‹œ ์ง„ํ–‰์ด ๋น ๋ฅด๊ณ  ๋‚ด์„ฑ๋„ ์ž˜ ์ƒ๊น€.
โ€ข
Tb๋ฅผ ์˜์‹ฌํ•˜๋Š” ๊ฒฝ์šฐ ๋ฐ˜๋“œ์‹œ HIV test๋„ ๊ฐ™์ด ํ™•์ธํ•ด์•ผ ํ•œ๋‹ค.

G2. Multi drug-resistant tuberculosis

โ€ข
INF์™€ RIF์— ๋‚ด์„ฑ ๋ณด์ด๋Š” ๊ฒฝ์šฐ
โ€ข
์ด์ „์— Tb ์น˜๋ฃŒ๋ณ‘๋ ฅ
โ€ข
MDR-Tb ๋…ธ์ถœ๋ ฅ
โ€ข
4๊ฐœ์›”์˜ standard tx ํšจ๊ณผ ์—†์„ ๋•Œ โ†’ Multidrug-resistant Tb ์น˜๋ฃŒ๋Š” culture ๊ฒฐ๊ณผ์— ๋”ฐ๋ผ combination therapy, refractory ํ•œ ๊ฒฝ์šฐ์— ์ถ”๊ฐ€์ ์œผ๋กœ ์ˆ˜์ˆ ์  ์น˜๋ฃŒ, delamanid ์™€ ๊ฐ™์€ ์ƒˆ๋กœ์šด ์•ฝ์ œ์˜ ๊ฐœ๋ฐœ

G3. Extensive drug-resistant tuberculosis

โ€ข
INH์™€ RIF + fluoroquinolone ๋‚ด์„ฑ๊ณผ ์ตœ์†Œํ•œ ํ•˜๋‚˜์˜ injectable second line medication์— ๋‚ด์„ฑ
โ€ข
๋ถˆ๋Ÿ‰ํ•œ ์˜ˆํ›„์™€ ๋†’์€ ์‚ฌ๋ง๋ฅ 

G4. Children

โ€ข
๋ฌด์ฆ์ƒ์ด ๋งŽ๊ณ  ์ฃผ๋กœ screening์ด๋‚˜ contact tracing์—์„œ ํ™•์ธ

(1) ์ฆ์ƒ

โ€ข
์ข€ ๋” ํฐ ์†Œ์•„๊ฐ€ ๋” ์ „ํ˜•์ ์ธ ์ฆ์ƒ : Fever, cough, wheezing, poor feeding, fatigue
โ€ข
5์„ธ ๋ฏธ๋งŒ : Miliary Tb, meningitis, ์น˜๋ฃŒ ๋ฐ˜์‘ ์—†๋Š” pneumonia, cervical lymphadenitis (m/c extrapul presentation)

(2) ์ง„๋‹จ

โ€ข
์•„์นจ 3๊ฐœ ์—ฐ์†๋œ gastric lavage, gastric aspirate sample๋กœ ๊ฒ€์‚ฌ
โ€ข
Newer test (IGRA, NAAT)๋Š” 5์„ธ ๋ฏธ๋งŒ์—์„œ๋Š” ์‚ฌ์šฉํ•˜์ง€ ๋ชปํ•œ๋‹ค. โ†’ ์ด ๋‚˜์ด๋Œ€์—๋Š” ๋ฉด์—ญ ๋ฐ˜์‘์ด ๋‹ค๋ฅผ ์ˆ˜ ์žˆ์–ด ๊ฒฐ๊ณผ ์‹ ๋ขฐํ•  ์ˆ˜ ์—†๋‹ค.

(3) ์น˜๋ฃŒ

โ€ข
skin test ๋˜๋Š” ์ž„์ƒ ์–‘์ƒ์— ๋”ฐ๋ผ ์‹œ์ž‘ํ•˜๋ฉฐ ์ง„๋‹จ์€ ์น˜๋ฃŒ๋ฐ˜์‘์— ๋”ฐ๋ผ ์ถ”์ •

G5. Miliary tuberculosis

โ€ข
ํŒŒ์ข…์„ฑ ๊ฒฐํ•ต(disseminated tb)์—์„œ lung์˜ gross appearance๋ฅผ ์˜๋ฏธํ•˜๋Š” historical term
โ€ข
Diffuse nodules (1~3mm) + positive lab test
โ€ข
์ผ์ฐจ ๋˜๋Š” ์žฌํ™œ๋™์„ฑ ๊ฒฐํ•ต์˜ ํ˜ˆํ–‰์„ฑ ์ „ํŒŒ๋กœ ๋†’์€ ์‚ฌ๋ง๋ฅ ์„ ๋ณด์ž„
โ€ข
More rapid, Severe, MOF, Shock, ARDS